Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

33%

2 of 6 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1

4(66.7%)

N/A

2(33.3%)

6Total

Phase 1(4)

N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT04785794Phase 1Completed

Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old

Role: lead

NCT05163847Phase 1Completed

Safety and Immunogenicity of Cam2020 M2SR H3N2 Monovalent Influenza Vaccine Alone or With Licensed IIV in Older Adults

Role: lead

NCT03999554Phase 1Completed

Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines

Role: lead

NCT02822105Phase 1Completed

Safety and Immunogenicity Study of H3N2 M2SR Monovalent Influenza Vaccine in Healthy Volunteers

Role: lead

NCT01767337Not ApplicableCompleted

Intracutaneous Delivery of Varied Dose Volumes of Saline

Role: lead

NCT01767324Not ApplicableCompleted

Site Selection for Intracutaneous Saline Delivery

Role: lead

All 6 trials loaded